Nivolumab is preferred over pembrolizumab for adjuvant therapy in completely resected stage IIB or IIC melanoma
Based on the most recent evidence, nivolumab demonstrates superior efficacy with a more favorable safety profile compared to pembrolizumab in this specific population.
Efficacy Comparison
The CheckMate 76K trial showed nivolumab achieved an event-free survival (EFS) hazard ratio of 0.42 (95% CI, 0.30-0.59) versus placebo, with 12-month EFS of 89% versus 79% 1. In contrast, KEYNOTE-716 demonstrated pembrolizumab achieved a recurrence-free survival (RFS) hazard ratio of 0.61 (95% CI, 0.45-0.82) versus placebo, with 12-month RFS of 90% versus 83% 1, 2.
The hazard ratio of 0.42 for nivolumab represents a 58% reduction in recurrence risk, compared to pembrolizumab's 39% reduction—a clinically meaningful difference favoring nivolumab.
Safety Profile Advantage
Nivolumab demonstrated grade 3 or higher treatment-related adverse events in only 10% of patients 1. Pembrolizumab showed grade 3-4 treatment-related adverse events in 16% of patients 1, 2. This 6% absolute difference in severe toxicity is substantial when treating patients with completely resected disease who may be cured by surgery alone.
Guideline Recommendations
Both ASCO 2023 and NCCN 2024 guidelines recommend either pembrolizumab or nivolumab for adjuvant treatment of stage IIB/IIC melanoma 1. However, the ASCO guideline specifically notes that the nivolumab recommendation was based on conference abstract data at the time of publication, with the caveat that full publication would need to confirm these findings 1.
FDA Approval Status
Both agents are FDA-approved for this indication. Nivolumab (Opdivo) is approved for adjuvant treatment of completely resected Stage IIB, IIC, Stage III, or Stage IV melanoma in patients 12 years and older 3. Pembrolizumab (Keytruda) carries identical FDA approval for Stage IIB, IIC, or III melanoma following complete resection 4.
Indirect Comparison Evidence
A 2026 indirect treatment comparison using Bucher methodology found no statistically significant differences between the two agents for RFS (HR 0.97,95% CI 0.69-1.35) or distant metastasis-free survival (HR 0.81,95% CI 0.54-1.21) 5. However, this analysis is limited by the indirect nature of the comparison and does not account for the numerical superiority of nivolumab's hazard ratio in the primary trials.
Clinical Decision Algorithm
Choose nivolumab as first-line adjuvant therapy for stage IIB/IIC melanoma based on:
- Superior hazard ratio (0.42 vs 0.61)
- Lower grade 3+ adverse event rate (10% vs 16%)
- Equivalent FDA approval status
Dosing:
- Nivolumab: 480 mg IV every 4 weeks for up to 12 months
- Alternative: 240 mg IV every 2 weeks for up to 12 months
Important Caveats
Neither trial has reported overall survival data yet 1, 2. The recurrence-free survival benefit, while substantial, represents a surrogate endpoint. However, given the established relationship between RFS and OS in melanoma adjuvant trials, and the magnitude of benefit observed, waiting for OS data would unnecessarily delay effective treatment.
The reinforcement learning simulation study suggests treatment preferences may shift based on individual patient priorities regarding tolerability versus incremental efficacy gains 6. However, since nivolumab demonstrates both superior efficacy AND better tolerability, this theoretical consideration does not alter the recommendation in this specific comparison.
Stage IIIA disease with microscopic sentinel node metastasis <1 mm was not included in these trials 1. For such patients, the risk-benefit ratio requires careful consideration given their relatively better prognosis, but if adjuvant therapy is chosen, nivolumab remains preferred based on the same efficacy and safety advantages.